# A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

> **NCT07462143** · PHASE2,PHASE3 · RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Colorectal (Colon or Rectal) Cancer

## Interventions

- **DRUG:** RC148 (Dose 1) plus Capecitabine and Oxaliplatin
- **DRUG:** RC148 (Dose 2) plus Capecitabine and Oxaliplatin

## Key facts

- **NCT ID:** NCT07462143
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-12
- **Primary completion:** 2027-05-12
- **Final completion:** 2030-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07462143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07462143, "A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07462143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*